COMPANY

Diakonos Oncology

Keywords: oncology Refractory Melanoma Pancreatic Adenocarcinoma Pancreatic Cancer Pancreatic Adenosquamous Carcinoma Glioblastoma DOC1021 Autologous DC Therapy

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Raise Seed · $11.4M · announced Aug 26, 2024 Company release ↗
Source quote
- Aug 26, 2024 · Company release ↗
  “Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial”

Raises announced in these releases: $11.4M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 6, 2026 Trial start Phase 1/Phase 2: DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma source ↗
Mar 17, 2025 Trial start Phase 2: DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) source ↗
Aug 26, 2024 Raise Seed · $11.4M source ↗
Aug 3, 2020 Trial start Phase 1: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma · NCT04157127
2030-03 (ESTIMATED) · Phase 2 · DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) · NCT06805305
2031-01 (ESTIMATED) · Phase 1/Phase 2 · DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma · NCT07288112

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07288112	DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma	Phase 1/Phase 2	Recruiting	Apr 6, 2026	2031-01 (estimated)
NCT04157127	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma	Phase 1	Recruiting	Aug 3, 2020	2026-12 (estimated)
NCT06805305	DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)	Phase 2	Recruiting	Mar 17, 2025	2030-03 (estimated)